angiogenesis ͉ xenograft mouse model
I
n solid tumors, angiogenesis is closely related to tumor growth and metastatic potential. In addition, recent studies also suggest a role for angiogenesis in hematologic malignancies, including multiple myeloma (MM). Therefore, targeting angiogenesis is a potentially potent approach in cancer treatment (1) (2) (3) . Vascular endothelial growth factor (VEGF) (4) is present in the bone marrow (BM) microenvironment of patients with MM and associated with angiogenesis. The extent of angiogenesis has been correlated directly with plasma-cell proliferation and labeling index and is inversely related with patient survival (5) . Previous studies showed that VEGF is expressed and secreted by MM cells and BM stromal cells and, in turn, stimulates IL-6 secretion by BM stromal cells, thereby augmenting paracrine MM cell growth. Moreover, IL-6 enhances the production and secretion of VEGF by MM cells. VEGF and VEGFR-1 (Flt-1) are coexpressed in both MM cell lines and patient MM cells, and VEGF-triggered effects in MM cells are mediated via Flt-1. Importantly, binding of VEGF increases MM cell growth, survival, and migration, thereby demonstrating the crucial role of VEGF in MM cell pathogenesis in the BM milieu (3) .
A recent milestone in cancer therapy was the approval of the humanized monoclonal antibody against VEGF, bevacizumab (Avastin), by the U.S. Food and Drug Administration as a first-line therapy for metastatic colorectal cancer in February 2004. Bevacizumab represents the first cancer drug specifically designed to target VEGF and, thereby, inhibit tumor angiogenesis. Subsequent studies have demonstrated the effectiveness of bevacizumab in several other tumors, including non-small cell lung cancer, breast cancer, pancreatic cancer, melanoma, and metastatic renal-cell cancer, but only when combined with conventional chemotherapy (3, 6) . Besides bevacizumab, which is administered intravenously, many other VEGF inhibitors have been developed. Based upon their bioavailability profile, several VEGF receptor inhibitors were developed as small-molecule receptor tyrosine kinase inhibitors. In marked contrast to bevacizumab, small-molecule antiangiogenic receptor tyrosine kinase inhibitors including PTK/ZK222584 (7) have failed to mirror its chemosensitizing ability. Only recently have encouraging results for second-generation antiangiogenesis drugs including sorafenib (Bayer, West Haven, CT) and sutent (Pfizer, New York, NY) been reported in solid tumors (7) , and to date, their clinical efficacy in hematologic malignancies, including MM, is undefined.
Our and other prior studies have evaluated several firstgeneration small-molecule VEGF receptor inhibitors for their therapeutic activity in MM, including the receptor tyrosine kinase inhibitor PTK787/ZK222584 (Novartis Pharma, Basel, Switzerland) and the pan inhibitor of VEGF receptors GW654652 (GlaxoSmithKline). These VEGF receptor inhibitors showed significant anti-MM efficacy in vitro (3) .
Pazopanib (GW786034B; GlaxoSmithKline) is a novel orally available, small-molecule tyrosine kinase inhibitor of VEGF receptor -1, -2, and -3 with IC 50 values of 10, 30, and 47 nM, respectively (ʈ, 8). An initial nonrandomized, dose-escalation phase I study with pazopanib (GSK-VEG10003) showed stable disease or partial responses in relapsed/refractory patients with renal cell (RCC), Hurthle cell, neuroendocrine, GIST, adeno lung carcinoma, chondrosarcoma, leiomyosarcoma, and melanoma. Remarkably, of 12 patients with RCC, 7 patients had stable disease or tumor reduction and 1 patient had a partial response. Adverse side effects included manageable hypertension, tiredness and hair depigmentation (9) . Based on this study, several clinical studies are ongoing, including a multicenter phase III trial in metastatic renal cell carcinoma (VEG105192) (www.clinicaltrials.gov).
Here, we show both in vitro and in vivo antitumor activity of pazopanib in MM. These preclinical data already have provided the framework for a multicenter phase I/II study with pazopanib alone in patients with relapsed or refractory MM (www.clinicaltrials.gov).
Importantly, we also demonstrate synergistic cytotoxicity of lowdose pazopanib with conventional and novel therapeutics, strongly supporting its future clinical evaluation in combination regimens to increase efficacy, overcome drug resistance, reduce toxicity, and improve patient outcome.
Results
Pazopanib Selectively Inhibits VEGF-Triggered Flt-1-Phosphorylation and Activation of Downstream Signaling Molecules. Pazopanib (GW786034B) is a novel, orally available small-molecule inhibitor of human VEGF receptor -1, -2, and -3 ( Fig. 1a) (ʈ, 8) . We first tested whether pazopanib can abrogate VEGF-induced VEGF receptor-1 (Flt-1) tyrosine phosphorylation in MM cells. Pazopanib inhibited both VEGF-triggered Flt-1 tyrosine phosphorylation (1 and 5 min) (Fig. 1b) and activation of downstream signaling molecules (Akt-1 and ERK for 1, 5, and 30 min) (10 g/ml for 1 h) (Fig. 1c) . Taken together, these data show that pazopanib inhibits VEGF-triggered pathways in MM cells.
Pazopanib Inhibits MM Cell Growth, Survival, and Migration. The impact of pazopanib on MM cell growth, survival, and migration was investigated next. Our data show that pazopanib decreased growth (Fig. 1d) and survival ( Fig. 1e) in all MM cell lines tested, including dexamethasone-sensitive MM.1S, dexamethasoneresistant MM.1R, doxorubicin (Dox)-sensitive RPMI, Doxresistant RPMI (Dox40), IL-6-dependent INA-6, OPM2, and U266. Decreased survival consistently was observed with an IC 50 ranging between 5 and 15 g/ml pazopanib. Similar IC 50 values were obtained in cells derived from three MM patients. In contrast, survival of PBMCs derived from normal donors was affected only slightly at high concentrations of pazopanib, thereby suggesting a large therapeutic window (Fig. 1f ) . Pazopanib also inhibited VEGF-triggered MM cell migration in several MM cell lines (Fig.  1g ). These data demonstrate that pazopanib inhibits MM cell growth, survival, and migration in both cell lines and patient cells.
Pazopanib Suppresses VEGF-Induced Endothelial Cell Proliferation and
Migration. Increased microvessel density in MM patient BM specimens correlates with disease progression and poor prognosis (10, 11) . VEGF is an essential regulator of physiologic endothelial cell growth, permeability, and migration in vitro and in vivo. VEGFtriggered activation of ERK and phosphatidylinositol 3-kinase in endothelial cells is predominantly initiated by VEGFR-2 (KDR) autophosphorylation. We next tested whether pazopanib has direct effects not only on MM cells, but also on VEGF-induced signaling in endothelial cells. Our results show that pazopanib blocks both VEGF-triggered autophosphorylation of KDR (Fig. 2a) and downstream activation of ERK and Akt1 (Fig. 2b) , thereby inhibiting proliferation of endothelial cells (Fig. 2c) . During angiogenesis, activated endothelial cells form cellular networks starting with migration and alignment, followed by the development of capillary tubes and the sprouting of new capillaries. As shown in Fig. 2d , VEGF-triggered endothelial cell migration was blocked in a concentration-dependent manner by pazopanib. To evaluate tube formation by endothelial cells, we seeded human umbilical endothelial cells (HUVECs) and endothelial cells isolated from BM aspirates (MM ECs) on matrigel. The addition of VEGF enhanced human umbilical endothelial tubule formation in the control cultures, confirming its specific effects. Importantly, pazopanib blocked tubule formation in a dose-dependent manner (Fig. 2e) . Taken together, these results demonstrate that pazopanib inhibits VEGF-triggered endothelial cell growth, survival, migration, and tubule formation.
Pazopanib Blocks VEGF-Induced Up-Regulation of Adhesion Molecules on Endothelial and MM Cells and MM Cell Proliferation in a Coculture
System. Although the role of BM stromal cell and MM cell interaction conferring growth, survival, and drug resistance is well established, whether there is any interaction between endothelial cells and MM cells and its potential relevance in MM pathogenesis is unknown. Given the importance of VEGF in triggering MM cell growth and migration and its pivotal role in angiogenesis, endothelial cells may exert a previously unrecognized role in MM. Therefore, we next examined whether MM cell proliferation is influenced by the presence of endothelial cells. As shown in Fig. 3a , MM cell adhesion to endothelial cells up-regulates cell proliferation (Ϸ2-fold), which is markedly inhibited at pazopanib concentrations Ͼ1 g/ml. Of great interest are the mechanisms mediating this effect. VEGF up-regulates cell adhesion molecules ICAM-1 and VCAM-1 (12) , and our data show that pazopanib specifically blocks this up-regulation (Fig. 3b) . Pazopanib also down-regulates expression of very late antigen 4 (VLA-4, CD49d/CD29, or integrin ␣4␤1) and lymphocyte function-associated antigen-1 (LFA-1, CD11a/ CD18, or integrin ␣L␤2) on MM cells (Fig. 3c) . Consequently, pazopanib quantitatively decreases adhesion of MM tumor cells to endothelial cells in an in vitro adhesion assay by using calcein-AM (Fig. 3d) . Moreover, attachment of EGFP/MM cells to endothelial tubules is significantly decreased in the area of vascular branching points (Fig. 3e) . These data therefore show that endothelial cells promote tumor cell growth via direct cell-cell contact and, conversely, that pazopanib specifically inhibits these effects.
Pazopanib Prolongs Survival in a Xenograft Mouse Model by Induction
of Tumor Cell Apoptosis and Inhibition of Tumor Angiogenesis. Previous studies using first-generation small-molecule VEGF receptor inhibitors showed significant anti-MM activity in vitro; however, they failed to inhibit MM tumor growth in vivo. Having demonstrated effects of pazopanib on both MM cells and endothelial cells in vitro, we next sought to assess the in vivo efficacy of pazopanib by using a MM xenograft mouse model. Previous pharmacokinetic studies of pazopanib in xenograft models have shown tolerability without any significant side effects (13) . Immune-deficient beigenude-xid (BNX) mice were inoculated s.c. in the flank with 3 ϫ 10 7 MM.1S cells. When the tumors reached a palpable size, mice were randomized into two treatment groups (30 mg/kg and 100 mg/kg) and one control group. Pazopanib was administered daily by oral gavage over a five-week period. Tumor growth in treated mice was significantly delayed (30 mg/kg) or almost totally inhibited (100 mg/kg) compared with the control group (Fig. 4a) . However, tumors rapidly regrew after cessation of treatment at day 30. Using Kaplan-Meier and log-rank analysis, the mean overall survival (OS) was 20 days [95% confidence interval, 18-23 days] in the control cohort versus 41 days (95% confidence interval, 34-49 days) and 51 days (95% confidence interval, 46-56 days) in groups treated with 30 mg/kg and 100 mg/kg pazopanib, respectively (Fig.  4b) . Statistically significant prolongation in mean OS compared with control mice was observed in animals treated with 30 mg/kg (P ϭ 0.0016) and 100 mg/kg (P ϭ 0.0007). Importantly, treatment with either the vehicle alone or pazopanib did not affect body weight (Fig. 4c) . Large areas of cells with condensed nuclei were seen in H&E stains of pazopanib-treated tumors, consistent with tumor cell apoptosis or necrosis (Fig. 4d) . Consistent with these data, TUNEL assays on tumor sections from treated versus control mice showed significantly increased apoptosis (Fig. 4e) . Finally, angiogenesis was reduced markedly within tumors of pazopanibtreated versus nontreated mice, as evidenced by CD31 staining (Fig.  4f ) . Taken together, these results demonstrate in vivo inhibition of tumor growth, increased MM cell apoptosis, and decreased angiogenesis, associated with prolongation of survival.
Synergistic Effects of Pazopanib with Conventional and Novel Therapies in a Tumor Cell-Endothelial Cell Coculture. Given the discrepancy between the marked antitumor activity of antiangiogenic inhibitors (e.g., VEGF receptor inhibitors) in animal models and the disappointing clinical results when these agents are used alone, ongoing trials are evaluating these agents with combination chemotherapy (6) . In vitro combination experiments in MM historically have proven to be highly predictive of their therapeutic value in patients. For example, based on our preclinical data, cotreatment regimens such as thalidomide and dexamethasone (14) and bortezomib and dexamethasone (15) already have been translated successfully into the clinical setting by our own and other groups (16) . We therefore next sought to assess the impact of combinations of pazopanib with novel and conventional therapies in MM cellendothelial cell cocultures. Isobologram analysis demonstrates that combination regimens of pazopanib with immunomodulatory drug (IMiDs) such as lenalidomide (Table 1 ) and actimid (data not shown), bortezomib, and melphalan induce synergistic cytotoxicity [combination index (CI) Ͻ1]. Interestingly, inhibition of caspase-8 (IETD-FMK) significantly decreased pazopanib-triggered MM cell death, whereas inhibition of caspase-9 (LEHD-FMK) had only a moderate effect (data not shown). Bortezomib triggers both caspase-8-and caspase-9-mediated MM cell death (17) . Furthermore, bortezomib, like thalidomide and the immunomodulatory drugs, also inhibits endothelial cell growth. Taken together, these data demonstrate the synergistic effect of low-dose pazopanib with conventional and novel therapeutics, providing the framework for combination clinical trials to increase efficacy, overcome drug resistance, and reduce toxicity.
Pazopanib-Triggered Transcriptional Changes.
To further delineate pazopanib-targeted molecular pathways in MM cells, we performed gene expression profiling of MM cells treated with pazopanib (5 g/ml for 2, 6, and 12 h) versus control cells (2, 6 , and 12 h). Early (2 h) dysregulation of several cancer-relevant genes and pathways was evident. For example, interleukin and chemokine receptors, several members of the TGF-␤ pathway, cyclins, and genes belonging to the ubiquitin and the insulin-receptor pathways were modulated. In addition, gene ontology analysis by using MappFINDER (18) [supporting information (SI) Fig. 5a ] demonstrated significant up-regulation of genes within the proapoptotic gene ontology group, including BCL2L11, BBC3 (PUMA), PMAIP1 (NOXA), BNIPL3, and Caspase-1, and significant downregulation of genes within the mitosis control pathway, including BUB1B, Aurora kinase A, Separin, Wee1, and CDC25A. Interestingly, Kops et al. (19) recently demonstrated that down-regulation of BUB1B leads to inhibition of the mitotic checkpoint, thereby inducing apoptosis in human cancer cells through massive chromosomal loss. Ongoing studies are evaluating the role of BUB1B in MM pathogenesis.
Furthermore, several gene products associated with MM pathogenesis including MMSET, Maf, and Syndecan 1 (CD138 and SDC1) were reduced markedly in pazopanib-treated MM cells. c-Myc was the gene most down-regulated compared with control (Ͼ30 fold reduction at 2 h, with further down-regulation at subsequent time points) (SI Fig. 5 a and b) .
At later time points, other cancer-relevant genes and pathways were dysregulated, including down-regulation of survivin, Mcl-1, caveolin-1 (SI Fig. 5c ), IL6 receptor, insulin-like growth factor 1 receptor, intergrins ␤7 and ␣4 (data not shown), and up-regulation of p21 (SI Fig. 5c ).
Deletion of c-Myc Results in Decreased Production and Secretion of VEGF.
Our results identified transcriptional changes of several cancer-related genes and signaling pathways. Specifically, c-Myc showed the most dramatic reduction in expression after pazopanib treatment. Based on these findings, we sought to identify possible functional sequelae of c-Myc down-regulation. Specifically, recent reports have demonstrated that c-Myc regulates VEGF production in B cells, identifying VEGF as a mediator of c-Myc-induced angiogenesis (20) (21) (22) . We therefore tested whether c-Myc plays a major role on VEGF production and angiogenesis also in MM cells.
To identify the specific functional impact of c-Myc inhibition on VEGF production and secretion, we transiently transfected MM.1S cells with c-Myc siRNA. As shown in SI Fig. 6a , c-Myc protein expression was down-regulated significantly by transfection with c-Myc, but not control, siRNA. We observed a decrease in mRNA levels of VEGF 145 and VEGF 165 , but not VEGF 121 (23) (SI Fig. 6b) , and a decrease of VEGF secretion (SI Fig. 6c ) in c-Myc-depleted cells. Besides these results showing the requirement of c-Myc for autocrine VEGF secretion by MM cells, our data also demonstrate that targeted c-Myc down-regulation inhibits proliferation of both MM cells alone and cell proliferation in endothelial cell-MM cell cocultures (SI Fig. 6d) . Similarly, pazopanib down-regulates VEGF mRNA levels after 12 h (SI Fig. 6e) , as observed in siRNA transfectants. Taken together, these data show that pazopanib inhibits c-Myc in MM cells, thereby decreasing VEGF production and secretion.
Discussion
The BM microenvironment is comprised of a heterogeneous population of cells promoting growth, survival, and drug resistance of MM cells due to both direct cell-to-cell contact and cell-toextracellular-matrix contact and by growth factors and chemokines secreted by tumor cells, stromal cells, and distant nonhematopoietic organs (3). Increased levels of VEGF are present in the BM of MM patients with progressive disease and associated with increased angiogenesis (10, 11) . Preclinical studies show that VEGF directly triggers MM cell growth, migration, and survival, increases osteoclast activity and chemotaxis, and inhibits dendritic cell maturation, thereby potentially contributing to the clinical features of MM, including lytic bone lesions and immune deficiency (3). We and others therefore suggested that direct and/or indirect targeting of VEGF and its receptors may provide a potent therapeutic approach in the treatment for this incurable disease.
Because of acceptable tolerability and preliminary evidence of clinical activity in solid tumors (9), we here characterized the effect of the novel, orally available, small-molecule VEGF receptor inhibitor pazopanib on MM cell growth in the BM milieu. Specifically, our data demonstrate that pazopanib inhibits tumor cell growth, survival, and migration as well as endothelial cell growth, migration, and vessel formation. Moreover, we identify a role of endothelial cell-tumor cell binding in promoting MM cell proliferation that, at least in part, is mediated via VEGF-triggered upregulation of integrins. Pazopanib, by decreasing expression of integrins on both MM cells and endothelial cells, abrogates MM cell adhesion to endothelial cells, thereby inhibiting MM cell proliferation. VEGF-triggered effects in MM cells are mediated predominantly via VEGF-R1 and, in endothelial cells, predominantly via VEGF-R2. However, it is possible that pazopanib, similar to imatinib mesylate and the novel Abl inhibitors AMN107 and BMS354825, also targets other tyrosine kinases. Indeed, inhibition of PDGF receptor ␣ and ␤ and c-Kit activity has been observed with pazopanib, although at IC 50 values significantly higher than those for inhibition of VEGF receptors (ʈ, 13). However, to define potential off-site targets of pazopanib in detail, we are initiating comparative in vivo studies of pazopanib and VEGF-blocking antibodies, e.g., DC101 (ImClone), B20-4, and G6 (Genentech) (24, 25) .
Importantly, pazopanib is a VEGF receptor inhibitor, which inhibits in vivo tumor growth, increases MM cell apoptosis, decreases angiogenesis, and prolongs host survival in a xenograft model of human MM. However, tumors regrew rapidly after treatment was stopped at day 30. The discrepancy between marked anti-tumor activity of antiangiogenic inhibitors (e.g., VEGF receptor inhibitors) in animal models versus the disappointing clinical results when used as single agents has resulted in their use with combination chemotherapy (6) . Besides increasing the efficacy of chemotherapeutics, this strategy may (i) allow use of doses significantly below the maximum tolerated dose, thereby decreasing adverse side effects, and (ii) permit drug administration for prolonged uninterrupted periods, thereby preventing development of drug resistance or even overcoming drug resistance (26) (27) (28) . Therefore, administration of VEGF receptor inhibitors in combination with other drugs may be required to achieve maximal efficacy. Specifically, our data demonstrate a synergistic effect of low-dose pazopanib with conventional and novel therapeutics, providing the basis for combination clinical trials to increase efficacy, overcome drug resistance, and reduce toxicity. Besides its use in combination with other chemotherapeutics, the clinical success of pazopanib likely will depend also on tumor stage and prior treatment (29-31).
Finally, further delineation of pazopanib-triggered effects in MM cells by using gene expression and signaling network analysis shows transcriptional changes of several cancer-related genes and signaling pathways, most significantly c-Myc. Using siRNA, we confirm the role of c-Myc in VEGF production and secretion and, thereby, angiogenesis in MM.
Based on these preclinical data, a multicenter phase I/II study with single agent pazopanib is ongoing in patients with relapsed or refractory MM. Importantly, our studies additionally demonstrate synergistic cytotoxicity of low-dose pazopanib with conventional and novel therapeutics, strongly supporting its future clinical evaluation in combination regimens to increase efficacy, overcome drug resistance, reduce toxicity, and improve patient outcome. Although the present study focuses only on the effects of pazopanib on tumor and endothelial cells, pazopanib also may abrogate other sequelae of VEGF within the MM BM microenvironment. Specifically, it may block VEGF stimulation of osteoclast activity and release VEGF-mediated suppression of dendritic cell maturation, with resultant clinical benefits of decreased bone disease and improved immune function. Microarray Assay. Total RNA was isolated from pazopanib pretreated or untreated MM.1S cells by using TRIzol reagent (Invitrogen, Carlsbad, CA). U133A 2.0 arrays were hybridized with biotinylated in vitro transcription products (10 g per chip) , as per manufacturer's instructions, within the Dana-Farber Cancer Institute Microarray Core Facility and then analyzed by using a Gene Array Scanner (Affymetrix). CEL files were obtained by using Affymetrix Microarray Suite 5.0 software. The DNA Chip Analyzer (34) was used to normalize all CEL files to a baseline array with overall median intensity, and the model-based expression (perfect match minus mismatch) was used to compute the expression values. Probes showing at least 1.5-fold difference between control and pazopanib-treated cells at 2, 6, and 12 h were included in the analysis. The average fold change at the three time points was used for the analysis by using GenMAPP (35) . Gene ontology analysis was performed by using MappFINDER (18) . A Z score Ͼ2 was considered significant (18) . The same data also were analyzed through the use of Ingenuity Pathways Analysis (Ingenuity Systems). Cell viability, as assessed by trypan blue exclusion, was Ͼ85% in all pazopanib-treated cells during times indicated.
Reverse Transcription PCR Analysis of VEGF. Total RNA was prepared with TRIzol reagent according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized by means of SuperScript One-Step RT-PCR system, as described in ref. 23 . The integrity of messenger RNA of all samples was confirmed by amplification of GAPDH. PCR products were separated on a 1% agarose gel and photographed.
ELISA. Cyokine levels were measured in supernatants from coculture systems as described in ref. 23 .
In Vitro Angiogenesis Assay. The antiangiogenic potential of pazopanib was studied by using an in vitro angiogenesis assay kit (Chemicon, Temecula, CA) as per manufacturer's instructions. Tube formation was assessed by using an inverted light/ fluorescence microscope at ϫ4-ϫ10 magnification.
FACS Analysis. MM.1S cells were cultured for 6 h in the presence or absence of pazopanib, washed, and then stained with specific Abs directed against CD11a (LFA-1) and CD49d (VLA-4) (BD Biosciences Pharmingen, San Diego, CA) and analyzed by using indirect immunofluorescence assays and flow cytometric analysis.
Cell Adhesion Assays. Adhesion assays were performed by using the Vybrant Cell Adhesion Assay Kit (Molecular Probes, Eugene, OR) as described in ref. 36 . All experiments were done in triplicate.
MM Xenograft Mouse Model. To determine the in vivo anti-MM activity of pazopanib, mice were inoculated s.c. in the right flank with 3 ϫ 10 7 MM.1S MM cells in 100 l of RPMI medium1640, together with 100 l of Matrigel (Becton Dickinson Biosciences, Bedford, MA). When the tumor was measurable, mice were assigned to indicated pazopanib treatment groups or a control group. Pazopanib was suspended in 0.5% hydroxypropylmethyl cellulose (Sigma-Aldrich, St. Louis, MO) and 0.1% Tween-80 (Sigma-Aldrich) in water as a vehicle (pH 1.3-1.5) and given daily by oral gavage for indicated periods (37) . The control group received the carrier alone at the same schedule and route of administration. Tumor burden was measured every other day by using a caliper [calculated volume ϭ (4 / 3) ϫ (width / 2) 2 ϫ (length / 2)]. Animals were killed when their tumor reached 2 cm or when the mice became moribund. Survival was evaluated from the first day of treatment until death (38) .
Immunohistochemistry. Four-micrometer-thick sections of formalin-fixed tissue were used for TUNEL staining and staining with CD31 Ab (Becton Dickinson Pharmingen) in a humid chamber at room temperature, as in ref. 38 . For image capturing, the Leica DM IRB microscope was connected to an Optimetrics camera and exported to MagnaFire software. Statistical Analysis. Statistical significance of differences observed in VEGF-treated versus control cultures was determined by using an unpaired Student's t test. The minimal level of significance was P Ͻ 0.05. Overall survival in animal studies was measured by using the Kaplan-Meier method, and results are presented as the median overall survival, with 95% confidence intervals.
